- Brand name:
- Pharmaceutical Company:
- Condition/Indication: Prevention of lower respiratory tract illness (LRTI) caused by RSV
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 July 2025 PBAC Meetings - (PDF 2MB)
- Public Summary Document (PSD) November 2024 July 2025 PBAC Meetings - (Word 1.4MB
Respiratory Syncytial Virus Vaccine – November 2024 – July 2025
Respiratory Syncytial Virus Vaccine; Injection (0.5 mL); Abrysvo® – November 2024 – July 2025
Last updated
5 June 2025